Actively Recruiting Prostate Cancer Clinical Trials Summary
By Class of Drug


Non-Steroidal Anti Androgens

These drugs work by preventing the active form of testosterone (also known as DHT) from stimulating the prostate and prostate cancer cells to grow. 

Study Name

Drug

Sponsor

Phase

Clinical Trials Link

PHEN Link

ENACT

enzalutamide (Xtandi)

Astellas Pharma

2

Clinicaltrials.gov

PHEN Information

ARASENS

darolutamide

Bayer

3

Clinicaltrials.gov

PHEN Information

ATLAS

apalutamide (Erleada)

Aragon Pharmaceuticals

3

Clinicaltrials.gov

-

PANTHER

apalutamide (Erleada ) & abiraterone (Zytiga)

Janssen Scientific

2

Clinicaltrials.gov

-

CYPIDES

ODM-208

Orion Pharma

2

Clinicaltrials.gov

-

Safety, Tolerability, and PK of GT0918

proxalutamide

Suzhou Kintor Pharma

2

Clinicaltrials.gov

-


GNRH Antagonist

This class of drugs prevents the release of certain hormones that stimulate testosterone production in the body. The decrease in testosterone production leads to less prostate and prostate cancer cell stimulation. 

Study Name

Drug

Sponsor

Phase

Clinical Trials Link

PHEN Link

HERO

relugolix

Myovant Sciences GmbH

3

Clinicaltrials.gov

-

PRONOUNCE

degarelix (Firmagon)

Ferring Pharmaceuticals

3

Clinicaltrials.gov

-

 

PARP Inhibitors

This class of drugs is a type of targeted therapy that inhibits a tumor cell’s ability to repair itself, causing them to die. The patients with tumors that have evidence of genetic mutations are most likely to benefit from PARP Inhibitor treatment. 

Study Name

Drug

Sponsor

Phase

Clinical Trials Link

PHEN Link

PROfound

olaparib (Lynparza)

AstraZeneca

3

Clinicaltrials.gov

-

Talapro-1

talazoparib

Pfizer

2

Clinicaltrials.gov

-

TRITON2

rucaparib (Rubraca)

Clovis Oncology

2

Clinicaltrials.gov

PHEN Information

TRITON3

rucaparib (Rubraca)

Clovis Oncology

3

Clinicaltrials.gov

PHEN Information

Galahad

niraparib (Zejula)

Janssen R&D

2

Clinicaltrials.gov

-

IMANOL

olaparib (Lynparza)

Spanish Oncology Genito-Urinary Group

2

Clinicaltrials.gov

-

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

olaparib (Lynparza)

M.D Anderson Cancer Center

2

Clinicaltrials.gov

-

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

olaparib (Lynparza)

Northwestern University

2

Clinicaltrials.gov

-

Olaparib for BRCAness Phenotype in Pancreatic Cancer

olaparib (Lynparza)

AstraZeneca

2

Clinicaltrials.gov

-


Monoclonal Antibodies

These drugs work by blocking a variety of signals in the body that help to destroy cancer cells or inhibit their ability to grow. 

Study Name

Drug

Sponsor

Phase

Clinical Trials Link

PHEN Link

CheckMate 9KD

 

nivolumab (Opdivo)

Bristol-Myers Squibb

2

Clinicaltrials.gov

-

Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer

 pembrolizumab (Keytruda)

Merck Sharp & Dohme Corp.

2

Clinicaltrials.gov

-

Tremelimumab + Durvalumab Chemotherapy Naive CRPC

durvalumab (Imfinzi), tremelimumab

M.D. Anderson Cancer Center

2

Clinicaltrials.gov

-

IMbassador250

atezolizumab (Tecentriq)

Hoffmann-La Roche

3

Clinicaltrials.gov

-

 

Immunotherapy

This class of drugs stimulates the body’s own immune system to respond to cancerous cells. 

Study Name

Drug

Sponsor

Phase

Clinical Trials Link

PHEN Link

PrTK03

AdV-tk (ProstAtak)

Advantagene, Inc

3

Clinicaltrials.gov

-

VISION

 177Lu-PSMA-617

Endocyte

3

Clinicaltrials.gov

-

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

 

AD5-SGE-REIC/Dkk-3

Momotaro-Gene Inc.

2

Clinicaltrials.gov

-

A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

 

DCVAC/PCa, ONCOS-102

Sotio a.s.

2

Clinicaltrials.gov

-

Molecular Inhibitors

This class of drugs interferes with certain cell signals that prevent tumors from growing and helps facilitate the death of cancer cells. 

Study Name

Drug

Sponsor

Phase

Clinical Trials Link

PHEN Link

IPATential150

ipatasertib

Hoffmann-La Roche

3

Clinicaltrials.gov

PHEN Information

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414

LY3023414

Eli Lilly and Company

2

Clinicaltrials.gov

-

A Phase 2 Study of PCM-075 in Combination With Abiraterone and Prednisone

PCM-075

Trovagene, Inc.

2

Clinicaltrials.gov

-

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist

TRC253

Tracon Pharmaceuticals Inc.

2

Clinicaltrials.gov

-

ProSTAR

CPI-1205

Constellation Pharmaceuticals

2

Clinicaltrials.gov

-

Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

CORT125281

Corcept Therapaeutics

2

Clinicaltrials.gov

-

Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression

ribociclib (Kisqali)

Sidney Kimmel Cancer Center at Thomas Jefferson University

2

Clinicaltrials.gov

-

 

Chemotherapy

This class of drugs specifically interacts with cancer cells in a way that prevents them from multiplying and promotes cell death. 

 

Multiple Drug Interventions

The trials below have multiple drug mechanisms working to battle cancer in different ways. 

Study Name

Drugs

Sponsor

Phase

Clinical Trials Link

PHEN Link

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer

abiraterone, prednisone, Radium-223 dichloride, cabazitaxel, carboplatin, enzalutamide

Icahn School of Medicine at Mount Sinai

2

Clinicaltrials.gov

-

PEACE2

cabazitaxel, Pelvic radiotherapy, ADT

Unicancer

3

Clinicaltrials.gov

-

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

ADT+docetaxel+enzalutamide

Earle Burgess

2

Clinicaltrials.gov

-

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

avelumab (Bavencio) + talazoparib

Pfizer

2

Clinicaltrials.gov

-

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

cabozantinib + atezolizumab

Exelis

2

Clinicaltrials.gov

-

  

Multiple Drug Interventions

The trials below have multiple drug mechanisms working to battle cancer in different ways. 

Study Name

Drugs

Sponsor

Phase

Clinical Trials Link

PHEN Link

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer

abiraterone, prednisone, Radium-223 dichloride, cabazitaxel, carboplatin, enzalutamide

Icahn School of Medicine at Mount Sinai

2

Clinicaltrials.gov

-

PEACE2

cabazitaxel, Pelvic radiotherapy, ADT

Unicancer

3

Clinicaltrials.gov

-

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

ADT+docetaxel+enzalutamide

Earle Burgess

2

Clinicaltrials.gov

-

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

avelumab (Bavencio) + talazoparib

Pfizer

2

Clinicaltrials.gov

-

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

cabozantinib + atezolizumab

Exelis

2

Clinicaltrials.gov

-

Trial of NanoPac¨ Focal Therapy in Subjects With Prostate Cancer

NanoPac

NonOlogy

2

Clinicaltrials.gov

-

Cabazitaxel and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer

cabazitaxel (Jevtana)

University of California, Davis

2

Clinicaltrials.gov

-

PHEN,Inc. © 2018 All rights reserved